NasdaqCM:EXAS

Stock Analysis Report

Executive Summary

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States.

Snowflake

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Exact Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EXAS's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.0%

EXAS

1.0%

US Biotechs

0.3%

US Market


1 Year Return

18.0%

EXAS

6.7%

US Biotechs

12.5%

US Market

Return vs Industry: EXAS exceeded the US Biotechs industry which returned 6.7% over the past year.

Return vs Market: EXAS exceeded the US Market which returned 12.5% over the past year.


Shareholder returns

EXASIndustryMarket
7 Day-9.0%1.0%0.3%
30 Day-12.9%11.0%4.1%
90 Day-33.5%5.2%5.6%
1 Year18.0%18.0%7.6%6.7%15.0%12.5%
3 Year357.6%357.6%12.4%8.9%49.1%39.4%
5 Year250.7%250.7%6.4%1.4%62.8%44.7%

Price Volatility Vs. Market

How volatile is Exact Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Exact Sciences undervalued compared to its fair value and its price relative to the market?

44.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EXAS ($80.53) is trading below our estimate of fair value ($146.24)

Significantly Below Fair Value: EXAS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EXAS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: EXAS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate EXAS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: EXAS is overvalued based on its PB Ratio (14x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Exact Sciences forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

103.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EXAS's is expected to become profitable in the next 3 years.

Revenue vs Market: EXAS's revenue (49.6% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: EXAS's revenue (49.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EXAS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Exact Sciences performed over the past 5 years?

-9.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EXAS has a high level of non-cash earnings.

Growing Profit Margin: EXAS's current net profit margins (-29.8%) are higher than last year (-35.8%).


Past Earnings Growth Analysis

Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of -9.5% per year.

Accelerating Growth: Unable to compare EXAS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (67.8%).


Return on Equity

High ROE: EXAS has a negative Return on Equity (-28.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Exact Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: EXAS's short term assets ($1.3B) exceeds its short term liabilities ($480.7M)

Long Term Liabilities: EXAS's short term assets (1.3B) exceeds its long term liabilities (530.3M)


Debt to Equity History and Analysis

Debt Level: EXAS's debt to equity ratio (109.2%) is considered high

Reducing Debt: EXAS had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: EXAS has a high level of physical assets or inventory.

Debt Coverage by Assets: EXAS's debt is covered by short term assets (assets are 1.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EXAS has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if EXAS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Exact Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate EXAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EXAS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EXAS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EXAS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EXAS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Exact Sciences's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average management tenure


CEO

Kevin Conroy (53yo)

10.6yrs

Tenure

US$6,991,997

Compensation

Mr. Kevin T. Conroy serves as Director of Adaptive Biotechnologies Corporation since April 2019. Mr. Conroy serves as Director at ARYA Sciences Acquisition Corp. Mr. Conroy has been the Chief Executive Off ...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD6.99M) is below average for companies of similar size in the US market ($USD11.12M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.8yrs

Average Tenure

53yo

Average Age

Experienced Management: EXAS's management team is considered experienced (4.8 years average tenure).


Board Age and Tenure

5.0yrs

Average Tenure

64yo

Average Age

Experienced Board: EXAS's board of directors are considered experienced (5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.6%.


Management Team

  • D. Coward (54yo)

    Chief Administrative Officer

    • Tenure: 1.3yrs
    • Compensation: US$2.09m
  • Gary Frings

    Chief Information Officer

    • Tenure: 4.8yrs
  • Graham Lidgard (70yo)

    Chief Science Officer

    • Tenure: 10.3yrs
    • Compensation: US$2.08m
  • Kevin Conroy (53yo)

    Chairman of the Board

    • Tenure: 10.6yrs
    • Compensation: US$6.99m
  • Jeff Elliott (41yo)

    Chief Financial Officer

    • Tenure: 3yrs
    • Compensation: US$1.98m
  • Tim Caprez

    Chief Compliance Counsel & VP

    • Tenure: 4.8yrs
  • Ana Hooker (53yo)

    Senior Vice President of Operations

    • Tenure: 4.8yrs
  • Mark Stenhouse (52yo)

    President of Cologuard

    • Tenure: 1.6yrs
    • Compensation: US$3.86m
  • Megan Jones

    Associate Manager of Investor Relations

    • Tenure: 0yrs
  • Vic Parker

    Head of Sales

    • Tenure: 0.9yrs

Board Members

  • Andy Slavitt (52yo)

    Director

    • Tenure: 0.3yrs
  • Dan Levangie (68yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$272.47k
  • Mike Wyzga (64yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$274.97k
  • Kay Napier Zanotti (64yo)

    Independent Director

    • Tenure: 10.6yrs
    • Compensation: US$269.97k
  • Kevin Conroy (53yo)

    Chairman of the Board

    • Tenure: 10.6yrs
    • Compensation: US$6.99m
  • Eli Casdin

    Independent Director

    • Tenure: 2yrs
    • Compensation: US$474.41k
  • Kathleen Sebelius (71yo)

    Independent Director

    • Tenure: 0.7yrs
  • Tom Carey (57yo)

    Independent Director

    • Tenure: 6.6yrs
    • Compensation: US$256.47k
  • Jim Doyle (73yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$266.47k
  • Pierre Jacquet

    Director

    • Tenure: 0.3yrs

Company Information

Exact Sciences Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Exact Sciences Corporation
  • Ticker: EXAS
  • Exchange: NasdaqCM
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.455b
  • Shares outstanding: 129.83m
  • Website: https://www.exactsciences.com

Number of Employees


Location

  • Exact Sciences Corporation
  • 441 Charmany Drive
  • Madison
  • Wisconsin
  • 53719
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EXASNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2001
EXKDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2001

Biography

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a n ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/11 23:38
End of Day Share Price2019/11/11 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.